Additionally, the ORIENT‐31 Phase 3 trial, assessing a novel anti‐angiogenesis and immunochemotherapy regimen including sintilimab, IBI305, cisplatin, and pemetrexed for non‐squamous NSCLC patients post‐EGFR‐TKI therapy progression, reported a persistent PFS advantage in its interim findings [12]. Here, EGFR is linked to non-small cell lung carcinoma.